Market Overview - The Shanghai Composite Index rose by 0.38% on May 20, with 27 out of the 28 sectors experiencing gains, led by the beauty and personal care sector, which increased by 2.50% [2] - The electronic sector also saw an increase of 0.71% [2] Fund Flow Analysis - The main funds in the two markets experienced a net outflow of 1.037 billion yuan, with 18 sectors seeing net inflows [2] - The electronic sector had the highest net inflow of funds, totaling 2.673 billion yuan, followed by the pharmaceutical and biological sector with a net inflow of 1.555 billion yuan [2] Electronic Sector Performance - Within the electronic sector, 334 out of 461 stocks rose, with 7 hitting the daily limit [3] - The top three stocks with the highest net inflow were O-film Technology, with 1.788 billion yuan, followed by Yingfangwei and Wanrun Technology, with net inflows of 297 million yuan and 255 million yuan respectively [3] Top Gainers in Electronic Sector - O-film Technology saw a price increase of 9.97% with a turnover rate of 11.35% and a main fund flow of 1.788 billion yuan [4] - Yingfangwei increased by 10.04% with a turnover rate of 12.45% and a main fund flow of 297 million yuan [4] - Wanrun Technology rose by 10.03% with a turnover rate of 4.96% and a main fund flow of 255 million yuan [4] Top Losers in Electronic Sector - The stock with the highest net outflow was Guangzhi Technology, with a net outflow of 173.218 million yuan and a price increase of 4.61% [5] - Hanwujing had a net outflow of 143.987 million yuan with a price increase of 0.16% [5] - Landai Technology experienced a net outflow of 134.810 million yuan with a price decrease of 2.25% [5]

利扬芯片今日涨15.49%，成交额11.32亿元， 换手率22.58%，盘后龙虎榜数据显示，一机构专用席位净 买入6219.37万元。 ...

东海证券指出，我国创新药具备研发成本低、效率高的优点，或成为BD交易首选，中国有望成为低成本研发与生产中心，加速从"仿制跟随"向"创新主 导"转型。大型跨国药企在更严格的定价体系下可能积极寻求降低研发生产成本的路径，我国CXO产业链或将进一步巩固市场地位。仿制药方面，美国仿制 药市场因价格压缩可能引发生产商退出，导致供应短缺，我国具备ANDA批件积累的仿制药企业有望抢占市场份额。建议关注创新药链、器械设备、中药、 医疗服务、连锁药店等细分板块及个股的投资机会。 科创综指ETF华夏紧密跟踪上证科创板综合指数，上证科创板综合指数由上海证券交易所符合条件的科创板上市公司证券组成指数样本，并将样本分红计入 指数收益，反映上海证券交易所科创板上市公司证券在计入分红收益后的整体表现。 科创综指ETF华夏(589000)，场外联接(华夏上证科创板综合ETF联接A：023719；华夏上证科创板综合ETF联接C：023720)。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 截至2025年5月20日 14:24，上证科创板综合指数(000680)上涨0.57%，成分股三生国健(688336)上涨19. ...

Core Viewpoint - The company is preparing for its 2024 annual shareholders' meeting, where various proposals will be discussed, including financial reports, profit distribution, and future financing plans. Group 1: Meeting Procedures - The meeting will require attendees to verify their identity and sign in 30 minutes prior to the start [3][4] - Shareholders have the right to speak, inquire, and vote during the meeting, with specific rules governing the order and duration of speeches [4][5] - Voting will be conducted through a combination of on-site and online methods, with results announced after the meeting [5][6] Group 2: Financial Proposals - Proposal 1 involves the approval of the 2024 annual report and its summary, which has been reviewed by the board and supervisory committee [7] - Proposal 4 presents the 2024 financial settlement report, summarizing the company's financial performance for the year [8] - Proposal 5 outlines a profit distribution plan, indicating that no dividends will be distributed for 2024 due to a net loss of approximately 61.62 million yuan [9] Group 3: Compensation Plans - Proposal 6 discusses the compensation plan for non-independent directors for 2025, which will be based on company performance and industry standards [11] - Proposal 7 details the compensation for independent directors, set at 80,000 yuan per year before tax [12] - Proposal 8 outlines the compensation for supervisors, with the chair receiving 50,000 yuan per year before tax [12] Group 4: Financing and Stock Issuance - Proposal 9 seeks approval for a comprehensive credit limit of up to 2 billion yuan for 2025, with various forms of collateral to be used [13][14] - Proposal 10 requests authorization for the board to issue shares to specific investors under simplified procedures, with conditions outlined for the issuance [16][17] - The company aims to use the funds raised from the stock issuance for business-related projects and to supplement working capital [20] Group 5: Business Strategy and Market Position - The company focuses on high-end integrated circuit testing to meet the growing demand in sectors like automotive electronics and AI [27][28] - The shift towards electric and intelligent vehicles is driving the demand for automotive chips, which the company plans to capitalize on [28] - The company has established a comprehensive testing capacity and is adjusting its strategy to focus on market-driven project development [29][30]

广东利扬芯片测试股份有限公司 （广东省东莞市万江街道莫屋新丰东二路 2 号） 2024 年年度股东大会 会议资料 股票简称：利扬芯片 股票代码：688135 二零二五年五月三十日 广东利扬芯片测试股份有限公司 2024 年年度股东大会会议资料 | | | | 2024 | 年年度股东大会会议须知 | 2 | | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | 5 | | 议案一：《关于<2024 | 年年度报告>及其摘要的议案》 | 7 | | 议案二：《关于<2024 | 年度董事会工作报告>的议案》 | 8 | | 议案三：《关于<2024 | 年度监事会工作报告>的议案》 | 9 | | 议案四：《关于<2024 | 年度财务决算报告>的议案》 | 10 | | 议案五：《关于公司 | 2024 年度利润分配预案的议案》 11 | | | 议案六：《关于公司 | 2025 年度非独立董事薪酬方案的议案》 | 12 | | 议案七：《关于公司 | 2025 年度独立董事薪酬方案的议案》 | 13 | | 议案八：《关于公司 | 2025 年度监事薪酬方案的议案》 | 14 ...

证券时报•数据宝统计显示，今日科创板个股上涨的有88只，下跌的有487只。 资金流向方面，今日主力资金净流入的科创板股共有185只，其中，3只个股主力资金净流入超3000万 元，华熙生物主力资金净流入4047.09万元，净流入资金居首；光云科技、九号公司紧随其后，全天净 流入资金分别为3643.48万元、3420.34万元。主力资金净流出的有399只，净流出资金最多的是中芯国 际，该股今日下跌1.91%，全天主力资金净流出4.21亿元，其次是寒武纪、金山办公，主力资金净流出 分别为1.61亿元、1.21亿元。 从主力资金连续性进行观察，共有43只个股主力资金连续3个交易日以上持续净流入，连续净流入天数 最多的是瑞联新材、利扬芯片等2只股，主力资金均连续净流入9天。主力资金连续流出的个股有162 只，连续流出天数最多的是先锋精科，该股已连续21个交易日净流出；连续净流出天数较多的还有莱特 光电、三达膜等，主力资金分别连续流出14天、11天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | ...

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [7][5]. Core Views - The company's 2024 performance is under pressure, with a reported revenue of 488.13 million yuan, a decrease of 2.97% year-on-year, and a net profit attributable to shareholders of -61.62 million yuan, indicating a shift from profit to loss [1][2]. - The company is actively acquiring and expanding in the special vehicle chip sector, aiming to enhance its long-term growth in the automotive segment [2][4]. - The decline in revenue is attributed to mixed demand in end markets, with some consumer categories seeing growth while others, particularly high-performance and industrial control chips, faced significant declines [2][3]. Financial Summary - Revenue is projected to recover, with estimates of 598.15 million yuan in 2025, reflecting a growth rate of 22.54% [6][12]. - The company expects to achieve a net profit of 100.29 million yuan in 2025, a significant turnaround from the losses in 2024 [6][12]. - The EBITDA is forecasted to increase to 270.36 million yuan in 2025, indicating improved operational efficiency [6][12]. Strategic Developments - The company plans to expand its three-temperature testing capacity to meet the growing demand for high-reliability chips, including those for automotive applications [3][4]. - The acquisition of Guoxin Microelectronics is aimed at strengthening the company's focus on testing services for special chips, enhancing its competitive edge in the integrated circuit testing sector [4][5]. - The company is committed to high-quality development through both organic growth and strategic acquisitions, particularly in the automotive electronics and autonomous driving sectors [3][4].

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [8] Core Views - The company's 2024 performance is under pressure, with a reported revenue of 488.13 million yuan, a decrease of 2.97% year-on-year, and a net profit attributable to the parent company of -61.62 million yuan, indicating a shift from profit to loss [1][2] - The company is actively acquiring and expanding in the special vehicle chip sector, aiming to enhance its long-term growth in the automotive segment [2][4] - The company is focusing on expanding its three-temperature testing capacity and increasing R&D in automotive chip testing technologies, particularly for autonomous driving applications [3] Financial Performance Summary - In 2024, the company reported a revenue of 488.13 million yuan, down from 503.08 million yuan in 2023, with a projected revenue increase to 598.15 million yuan in 2025, representing a growth rate of 22.54% [7][12] - The net profit attributable to the parent company is expected to recover from -61.62 million yuan in 2024 to 100.29 million yuan in 2025, with further growth anticipated in subsequent years [5][12] - The company issued convertible bonds in 2024, raising 520 million yuan, with a significant portion already converted into equity [5] Strategic Developments - The company plans to acquire 100% of the shares of Guoxin Micro, a third-party integrated circuit testing technology provider, to strengthen its focus on testing services and fill gaps in its capabilities [4] - The company is committed to enhancing its core business through both organic growth and strategic acquisitions, while also improving customer technology through collaboration [3]

资金流向方面，今日主力资金净流入的科创板股共有219只，其中，6只个股主力资金净流入超3000万 元，芯原股份主力资金净流入9530.11万元，净流入资金居首；财富趋势、大地熊紧随其后，全天净流 入资金分别为6264.27万元、4807.96万元。主力资金净流出的有366只，净流出资金最多的是恒玄科技， 该股今日下跌5.00%，全天主力资金净流出1.43亿元，其次是寒武纪、澜起科技，主力资金净流出分别 为9631.09万元、5655.58万元。 从主力资金连续性进行观察，共有55只个股主力资金连续3个交易日以上持续净流入，连续流入天数最 多的是迅捷兴，该股已连续11个交易日净流入；连续净流入天数较多的还有耐科装备、利扬芯片等，主 力资金分别连续流入10天、8天。主力资金连续流出的个股有132只，连续流出天数最多的是先锋精科， 该股已连续20个交易日净流出；连续净流出天数较多的还有莱特光电、三达膜等，主力资金分别连续流 出13天、10天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | - ...

广发证券股份有限公司 关于广东利扬芯片测试股份有限公司 2024 年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》等有关法律、法规的规定，广发证券股份有限公司（以下简称"广发证 券""保荐机构"）作为广东利扬芯片测试股份有限公司（以下简称"利扬芯 片""公司"）首次公开发行并上市的持续督导保荐机构，负责利扬芯片上市后 的持续督导工作，并出具本年度持续督导跟踪报告。 2024 年度，广发证券对利扬芯片的持续督导工作情况总结如下： | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并 | 保荐机构已建立健全并有效执行 | | | 针对具体的持续督导工作制定相应的工作计 | 了持续督导制度，已制定了相应的 | | | 划。 | 工作计划。 | | 2 | 根据中国证监会相关规定，在持续督导工作 | 保荐机构已与利扬芯片签订《承销 | | | 开始前，与上市公司或相关当事人签署持续 | 保荐协议》，该协议已明确了双方 | | | 督导协议，明确双方在持续督导期间的权利 | 在持续督导期间的权 ...